Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.
renske.altena@znb.nl.
Renske
R
Altena
Eric
E
van Roon
Richard
R
Folkeringa
Harry
H
de Wit
Mels
M
Hoogendoorn
D000368:Aged; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001281:Atrial Fibrillation / Q000628:therapy*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001026:Coronary Artery Bypass; D004344:Drug Incompatibility; D005260:Female; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
D000904:Antibiotics, Antitubercular; D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D002939:Ciprofloxacin; D000069552:Rivaroxaban; D012293:Rifampin
interaction; novel oral anticoagulants; pulmonary embolism